Germán Reyes-Botero

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria

Jaime Gállego Pérez‐Larraya, M. Lahutte, Grégorio Petrirena et al. · Neuro-Oncology · 2012 · 104 citations · Full text

High-grade Gliomas, Recurrent Glioblastoma, Response Assessment +18

Molecular analysis of diffuse intrinsic brainstem gliomas in adults

Germán Reyes-Botero, Marine Giry, Karima Mokhtari et al. · Journal of Neuro-Oncology · 2013 · 80 citations

Neuro-oncology, Neuroimaging Biomarkers, Molecular Analysis +12

Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression

Germán Reyes-Botero, Caroline Dehais, Ahmed Idbaïh et al. · Neuro-Oncology · 2013 · 67 citations · Full text

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

Germán Reyes-Botero, Stéphanie Cartalat‐Carel, Olivier Chinot et al. · The Oncologist · 2018 · 36 citations · Full text

Temozolomide after radiotherapy in recurrent “low grade” diffuse brainstem glioma in adults

Germán Reyes-Botero, Florence Laigle–Donadey, Karima Mokhtari et al. · Journal of Neuro-Oncology · 2014 · 25 citations

Neuro-oncology, Radiation Therapy, Brain Injury +10